Overview: Three new lawsuits have been filed on behalf of patients who suffered cerebral hemorrhaging after taking the blood thinner, Plavix. The suits were filed by Parker Waichman LLP on May 30th in the Supreme Court of New York, County of New York.
Product: Plavix (clopidogrel)
Manufacturer: Sanofi-Aventis, Bristol-Myers Squibb Co.
Side Effects & Complications
- Cerebral hemorrhage
- Thrombotic Thrombocytopenic Purpura (TTP)
- Gastrointestinal bleeding
- Internal bleeding
- Bone marrow damage
- Heart attack
One of the Plaintiffs includes a man from Honolulu, Hawaii. According to Parker Waichman’s press release, the man began taking Plavix in October 2009 and experienced a cerebral hemorrhage the following June. Another complaint was filed on behalf of a Shawnee, Kansas woman who started Plavix in August 2008 and suffered from a cerebral hemorrhage in June 2010. The third lawsuit was filed on behalf of a Louisiana woman who started Plavix in 2000 and developed a cerebral hemorrhage last June. All of the lawsuits allege severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering, loss of enjoyment of life and past, present and future medical expenses.
The lawsuits also claim that the manufacturers, Bristol-Myers Squibb and Sanofi-Aventis, failed to adequately test the drug for safety and effectiveness but marketed it nonetheless. According to the complaints, their negligent and/or fraudulent actions expose Plavix users to an increased risk of heart attack, stroke, internal bleeding, blood disorders and/or death.
According to the complaints, Plavix makers have made false and unsubstantiated claims about the drug, particularly in comparing it to Aspirin; Aspirin is also used to prevent ischemic events, but is less expensive. Apparently, the Defendants had claimed that taking Plavix in combination with Aspirin was safe in a promotional letter to doctors. The U.S. Food and Drug Administration (FDA) negated these claims in a 2001 warning letter, stating that this overstated the benefits of Plavix. Furthermore, a study published in the New England Journal of Medicine in 2006 comparing the effects of so-called “dual therapy” of Aspirin plus Plavix to Aspirin alone in preventing cardiovascular events found that the dual therapy did not have significant benefits over monotherapy with Aspirin.